Literature DB >> 1314232

In vitro response of human small-cell lung-cancer cell lines to chemotherapeutic drugs; no correlation with clinical data.

E F Smit1, E G de Vries, H Timmer-Bosscha, L F de Leij, J W Oosterhuis, R J Scheper, J J Weening, P E Postmus, N H Mulder.   

Abstract

Three cell lines derived from small-cell lung carcinoma (SCLC) tumors of patients who had no clinical response after treatment with a multi-drug regimen were compared to 3 cell lines derived from tumors of patients who, upon treatment, showed a complete clinical response. These 2 groups of cell lines were considered to represent the in vitro counterparts of the 2 extremes of the clinical spectrum of sensitivity for chemotherapeutic drugs in small-cell lung cancer. To assess whether the in vivo (in)sensitivity of a tumor to a certain drug regimen is retained in vitro, the cell lines were tested for drug sensitivity using the microtiter-well tetrazolium assay and the results were compared with the in vivo data. No correlation was found. Since in vitro models using cell lines are based on the assumption that a cell line reflects the properties of the tumor from which it is derived, several additional parameters such as MAb staining against different SCLC-associated antigens and DNA content were analyzed in the biopsies and the cell lines. The results showed that selection of discrete tumor-cell populations in vitro occurs. Results of in vitro chemosensitivity testing for individual SCLC patients should be interpreted with caution.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1314232     DOI: 10.1002/ijc.2910510115

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

Review 1.  P-glycoprotein-mediated multidrug resistance in normal and neoplastic hematopoietic cells.

Authors:  T Licht; I Pastan; M Gottesman; F Herrmann
Journal:  Ann Hematol       Date:  1994-10       Impact factor: 3.673

2.  Insight into the role of alternative splicing within the RBM10v1 exon 10 tandem donor site.

Authors:  Sarah J Tessier; Julie J Loiselle; Anne McBain; Celine Pullen; Benjamin W Koenderink; Justin G Roy; Leslie C Sutherland
Journal:  BMC Res Notes       Date:  2015-02-19

3.  RBM5 reduces small cell lung cancer growth, increases cisplatin sensitivity and regulates key transformation-associated pathways.

Authors:  Julie J Loiselle; Justin G Roy; Leslie C Sutherland
Journal:  Heliyon       Date:  2016-11-29

4.  RBM10 promotes transformation-associated processes in small cell lung cancer and is directly regulated by RBM5.

Authors:  Julie J Loiselle; Justin G Roy; Leslie C Sutherland
Journal:  PLoS One       Date:  2017-06-29       Impact factor: 3.240

5.  Comprehensive Metabolic Profiling of MYC-Amplified Medulloblastoma Tumors Reveals Key Dependencies on Amino Acid, Tricarboxylic Acid and Hexosamine Pathways.

Authors:  Khoa Pham; Allison R Hanaford; Brad A Poore; Micah J Maxwell; Heather Sweeney; Akhila Parthasarathy; Jesse Alt; Rana Rais; Barbara S Slusher; Charles G Eberhart; Eric H Raabe
Journal:  Cancers (Basel)       Date:  2022-03-03       Impact factor: 6.575

6.  Differential cytotoxicity of 19 anticancer agents in wild type and etoposide resistant small cell lung cancer cell lines.

Authors:  P B Jensen; I J Christensen; M Sehested; H H Hansen; L Vindeløv
Journal:  Br J Cancer       Date:  1993-02       Impact factor: 7.640

7.  The TdT-mediated dUTP nick end labeling assay precisely assesses the DNA damage in human tumor xenografts.

Authors:  H Kikuchi; S Ujiie; R Kanamaru
Journal:  Jpn J Cancer Res       Date:  1998-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.